S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

AUTL Autolus Therapeutics PLC

2.21

0.01 (0.45%)

01 Feb 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics PLC News

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Friday 17 January 2025 (2 weeks ago) • GlobeNewswire Inc.

Autolus Therapeutics Provides Business Updates and 2025 Overview
Monday 13 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Tuesday 10 December 2024 (2 months ago) • GlobeNewswire Inc.

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
Monday 2 December 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 12 November 2024 (3 months ago) • Edgar (US Regulatory)

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Tuesday 12 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 12 November 2024 (3 months ago) • Edgar (US Regulatory)

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Saturday 9 November 2024 (3 months ago) • GlobeNewswire Inc.

More Autolus Therapeutics PLC News Articles

S&P ASX 300 Metals and M...

National Australia Bank

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions